ClinicalTrials.gg
CompletedNCT01918098Updated Nov 14, 2017

Targin for Non-cancer Pain

A Phase 3 interventional study of Oxycodone/naloxone prolonged release tablets in Non Cancer Pain, sponsored by Mundipharma (China) Pharmaceutical Co. Ltd. Completed at 31 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-11-14.

Sponsored by Mundipharma (China) Pharmaceutical Co. Ltd (part of Mundipharma) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Pain by Mundipharma — none open to participants now, none under way, none of them phase 3. Pain · Mundipharma.

Enrollment
8th of 29
230 · median 120
Started
2013
with 3 others
Phase 3
12 of 33
none open now
Registered
19th of 33
by date

Among the 33 studies in Pain by Mundipharma, this one is the 8th largest by enrollment of the 29 interventional ones that give a count, is one of 4 that started in 2013, is one of 12 in phase 3, and was the 19th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

None of the 33 studies in Pain by Mundipharma is open now. The open studies under Pain, anywhere →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies in Pain by Mundipharma as a file.
02

Study summary

To determine the improvement in symptoms of constipation in subjects receiving treatment with oxycodone/naloxone prolonged release tablets (OXN) compared to oxycodone prolonged release tablets (OXY) based on the Bowel Function Index (BFI)

03

Conditions studied

  • Non Cancer Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Screening Inclusion criteria:

  • Males or females, 18 years of age or older
  • Clinical diagnosis of musculo-skeletal pain for 4 weeks or longer with non-malignant pain etiology at Visit 1. Possible etiologies are conditions related to intervertebral disc disease, spondylolisthesis and osteoarthritis; other similar non-malignant diseases are also eligible.
  • Patients with non-malignant pain that require around-the-clock opioid therapy (oxycodone equivalent of ≥10 mg/day and ≤50 mg/day) who are likely to benefit from WHO step III opioid therapy for the duration of the study
  • Patients who have been already treated with NSAIDs at least 2 weeks before enrolment are also eligible, but they should rate their pain (Pain Intensity Scale -"average pain" over the last 24 hours) as ≥4 on 0-10 scale."
  • Subjects are either taking opioid medication or willing to take opioids to treat their pain
  • Patients who are willing to use adequate and reliable throughout the study. Highly effective methods of birth control are defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as sterilization, implants, injectable, combined oral contraceptives, some IUDs (intrauterine Device, hormonal), sexual abstinence or vasectomized partner
  • Subjects willing and able to participate in all aspects of the study, including use of oral medication, completion of subjective evaluations, attending scheduled clinic visits, completing telephone contacts, and compliance with protocol requirements are evidenced by providing written
  • Subjects taking pre-study, non-opioid analgesics, and all other concomitant medications, including those medications for the treatment of depression and are considered necessary for the subject's welfare, and are anticipated to remain stable throughout the double-blind period of the study, and are to be continued under the supervision of the investigator, are eligible.

    • Patients who have been already treated with NSAIDs at least 2 weeks before enrolment are also eligible, but they should rate their pain (Pain Intensity Scale -"average pain" over the last 24 hours) as ≥4 on 0-10 scale.

Criteria for entry to the Double-Blind phase:

  1. Subjects continue to satisfy screening criteria outlined in the protocol
  2. Subject's OXY dose is between 10-50 mg/day
  3. Subjects who rate their pain (Pain Intensity Scale -"average pain" over the last 24 hours) as≤4 on 0-10 scale with less than or equal to two doses of Morphine Sulfate tablets rescue medication per day for either the last three consecutive days or four of the last seven days
  4. Subjects who have constipation induced, or worsened by their opioid study medication, as shown by:

    1. The subject's medical need for regular intake of laxatives to have at least 3 bowel evacuations per week, or having less than 3 bowel evacuations per week when not taking a laxative, respectively and
    2. The subjects' constipation was considered to be induced, worsened or maintained by their current study opioid medication and
    3. BFI value > 30.
  5. Subjects demonstrate compliance with laxative use, and completing appropriate and legible daily diaries
  6. Subjects taking daily fibre supplementation or bulking agents are eligible if they can be maintained on a stable dose and regimen throughout the study, and in the investigator's opinion are willing and able to maintain adequate hydration.

Screening Exclusion criteria:

  1. Females who are pregnant (positive β-hCG test) or lactating
  2. Any history of or with any to oxycodone, naloxone, bisacodyl, or related products
  3. Subjects currently taking the equivalent of > 50 mg/day Oxycodone PR
  4. Evidence of cardiovascular, renal, hepatic, gastrointestinal (paralytic ileus), or psychiatric disease, as determined by medical history, clinical laboratory tests, (ECG) results, and physical examination, that will place the subject at risk upon exposure to the study medication or that could confound the analysis and/or interpretation of the study results
  5. Subjects with evidence of impaired liver/kidney function upon entry into the study defined as (AST; SGOT), alanine aminotransferase (ALT; SGPT), or alkaline phosphatase levels >3 times the ; gamma glutamyltranspeptidase (GGT or GGTP) ≥ 5 times the upper limit of normal; total level outside of the reference range; and/or creatinine level outside of the reference range or >2 mg/dl, or in the investigator's opinion, liver and/or kidney impairment to the extent that the subject should not participate in this study
  6. Subjects with evidence of significant structural abnormalities of the gastrointestinal tract or any diseases/conditions that affect bowel transit
  7. Subjects who have required treatment for the diagnosis of irritable bowel syndrome (IBS)
  8. Subjects receiving hypnotics or other central nervous system (CNS) depressants that, in the investigator's opinion, may pose a risk of additional CNS depression with opioids study medication
  9. Surgery within 2 months prior to the start of the Screening Period, or planned surgery during the 12-week Double-blind Phase that may have affected GI motility or pain
  10. Subjects diagnosed with cancer, not including basal cell carcinoma
  11. Subjects with Rheumatoid Arthritis (RA)
  12. Subjects receiving opioid substitution therapy for opioid addiction (e.g., methadone or buprenorphine)
  13. Subjects with active alcohol or drug abuse and/or history of opioid abuse
  14. Subjects who participated in a clinical research study involving a new chemical entity or an experimental drug within 30 days of study entry (defined as the start of the Screening Period)
  15. Subjects presently taking, or who had taken naloxone or naltrexone within 30 days of study entry (defined as the start of the Screening Period).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
230 participants (actual)

Study arms

  • Experimental
    Oxycodone/naloxone prolonged release tablets

    Dose strength:5/2.5 mg,10/5mg, 20/10mg,PO,q12h.daily dose from 10/5mg to 50/25mg.treatment duration:12 weeks

    Drug: Oxycodone/naloxone prolonged release tablets

  • Active comparator
    Oxycodone prolonged release tablets

    Dose strength:5mg,10mg, 20mg,PO,q12h.daily dose from 10mg to 50mg.treatment duration:12 weeks

    Drug: Oxycodone/naloxone prolonged release tablets

Interventions

  • DrugOxycodone/naloxone prolonged release tablets
06

What researchers measure

Primary outcomes

  1. Bowel function index(BFI) 12 Weeks

    Time frame: 12 weeks

Secondary outcomes

  1. Modified BPI-SF-Average Pain over the last 24 hours

    Time frame: 12 weeks

07

Study locations

31 sites
  • Guangzhou First People's Hospital
    Guangzhou, Guangdong, China
  • Second Affiliated Hospital of Shan Tou University Medical College
    Shan Tou, Guangdong, China
  • Hebei General Hospital
    Shijiazhuang, Hebei, China
  • Beijing friendship hospital
    Beijing, China
  • Beijing Tiantan Hospital
    Beijing, China
  • Beijing Union hospital
    Beijing, China
  • Peking Union Medical College Hospital
    Beijing, China
  • Peking University Third Hospital
    Beijing, China
  • The first affiliated hospital of Bengbu medical collage
    Bengbu, China
  • The third Xiangya hospital of central south university
    Changsha, China
  • The thrid Xiangya Hospital of central south university
    Changsha, China
  • Xiangya hospital central south university
    Changsha, China
  • West China Hospital
    Chengdu, China
  • Daping Hospital
    Chongqing, China
  • South West hospital
    Chongqing, China
  • Fuzhou general hospital
    Fuzhou, China
  • The third affiliated hospital Sun yat-sen university
    Guangzhou, China
  • Guizhou Provincial People's Hospital
    Guizhou, China
  • The second affiliated hospital of Harbin medical university
    Harbin, China
  • Shandong Provincial Hospital
    Jinan, China
  • Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine
    Shanghai, China
  • Shanghai Changhai Hospital
    Shanghai, China
  • Shanghai Sixth People's Hospital
    Shanghai, China
  • Zhongshan Hospital Fudan University
    Shanghai, China
  • The first affiliated hospital of Shantou university medical college
    Shantou, China
  • The general hospital of Shenyang military
    Shenyang, China
  • The central hospital of Wuhan
    Wuhan, China
  • Tongji Hospital
    Wuhan, China
  • Union Hospital Tongji medical college
    Wuhan, China
  • The affiliated hospital of Xuzhou medical university
    Xuzhou, China
  • Second affiliated hospital of Zhejiang university
    Zhejiang, China
08

References and documents

Publications

  • Leng X, Zhang F, Yao S, Weng X, Lu K, Chen G, Huang M, Huang Y, Zeng X, Hopp M, Lu G. Prolonged-Release (PR) Oxycodone/Naloxone Improves Bowel Function Compared with Oxycodone PR and Provides Effective Analgesia in Chinese Patients with Non-malignant Pain: A Randomized, Double-Blind Trial. Adv Ther. 2020 Mar;37(3):1188-1202. doi: 10.1007/s12325-020-01244-x. Epub 2020 Feb 3. PubMed 32020565 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in Mar 2017, 42 months.

Of 105 industry-sponsored phase 3 interventional studies under Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 23. This study's 42 months is above that.

Counting every sponsor, half of 216 studies reached it within 18 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2013
First posted
Aug 7, 2013
StartActual
Sep 1, 2013
Primary completionActual
Mar 30, 2017
CompletionActual
Mar 30, 2017
Last update
Nov 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01918098
Responsible party
Sponsor
First posted
Aug 7, 2013
Start date
Sep 1, 2013
Primary completion
Mar 30, 2017
Completion
Mar 30, 2017
Last update
Nov 14, 2017

Study contacts

Victoria Yu
study director · Mundipharma, China

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion